| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year) 02/28/2022 | 3. Issuer Name and Ticker or Trading Symbol CTI BIOPHARMA CORP [ CTIC ] | |||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| 5. If Amendment, Date of Original Filed (Month/Day/Year) | ||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 3,565 | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (right to buy) | (1) | 04/12/2022 | Common Stock | 360 | 60.5 | D | |
| Stock Option (right to buy) | (2) | 03/24/2024 | Common Stock | 2,430 | 35.7 | D | |
| Stock Option (right to buy) | (3) | 03/17/2025 | Common Stock | 3,700 | 19.4 | D | |
| Stock Option (right to buy) | (4) | 05/18/2026 | Common Stock | 8,250 | 4.475 | D | |
| Stock Option (right to buy) | (5) | 03/01/2027 | Common Stock | 10,000 | 4.33 | D | |
| Stock Option (right to buy) | (6) | 09/29/2027 | Common Stock | 58,750 | 3.19 | D | |
| Stock Option (right to buy) | (7) | 05/16/2028 | Common Stock | 23,340 | 4.14 | D | |
| Stock Option (right to buy) | (8) | 02/19/2029 | Common Stock | 288,000 | 0.9489 | D | |
| Stock Option (right to buy) | (9) | 06/05/2030 | Common Stock | 210,000 | 1 | D | |
| Stock Option (right to buy) | (10) | 03/10/2031 | Common Stock | 115,000 | 3.3 | D | |
| Stock Option (right to buy) | (11) | 09/23/2031 | Common Stock | 210,000 | 3.05 | D | |
| Explanation of Responses: |
| 1. This option represents the right to purchase 360 shares of the Issuer's common stock and is fully vested. |
| 2. This option represents the right to purchase 2,430 shares of the Issuer's common stock and is fully vested. |
| 3. This option represents the right to purchase 3,700 shares of the Issuer's common stock and is fully vested. |
| 4. This option represents the right to purchase 8,250 shares of the Issuer's common stock and is fully vested. |
| 5. This option represents the right to purchase 10,000 shares of the Issuer's common stock and is fully vested. |
| 6. This option represents the right to purchase 58,750 shares of the Issuer's common stock and is fully vested. |
| 7. This option represents the right to purchase 23,340 shares of the Issuer's common stock and is fully vested. |
| 8. This option represents the right to purchase 288,000 shares of the Issuer's common stock and is fully vested. |
| 9. This option represents the right to purchase 210,000 shares of the Issuer's common stock and vests in equal semi-annual installments beginning on September 11, 2020 through March 11, 2023, subject to the Reporting Person's continued service to the Issuer. |
| 10. This option represents the right to purchase 115,000 shares of the Issuer's common stock and vests in approximately equal semi-annual installments beginning on September 10, 2021 through March 10, 2024, subject to the Reporting Person's continued service to the Issuer. |
| 11. This option represents the right to purchase 210,000 shares of the Issuer's common stock and vests 25% annually beginning on February 28, 2023, subject to the Reporting Person's continued service to the Issuer. |
| Remarks: |
| Senior Vice President and Chief Commercial Officer Exhibit 24 - Power of Attorney |
| /s/ Bruce J. Seeley, Attorney-in-fact for James K. Fong | 03/11/2022 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
